header logo image


Page 836«..1020..835836837838..850860..»

The North America diabetes care devices market is expected to reach US$ 15,300.0 Mn in 2027 from US$ 8,936.5 Mn in 2018 – PRNewswire

November 13th, 2019 6:54 am

NEW YORK, Nov. 12, 2019 /PRNewswire/ -- The North America diabetes care devices market is expected to reach US$ 15,300.0 Mn in 2027 from US$ 8,936.5 Mn in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05794734/?utm_source=PRN

The growth of the diabetes care devices market is primarily attributed to the growing geriatric population and rapid technological advancements in diabetes care devices.However, high cost of diabetes care devices and risks associated with the insulin delivery devices are likely to pose a negative impact on the market growth.

On the other hand, development of cost efficient pen needles is likely to have a positive impact on the growth of the North America diabetes care devices market in the coming years.The advancement in the field of the healthcare industry is driving to the players for more research and developments for insulin delivery devices.There are many methods to deliver insulin into the body such as needles, insulin pens and insulin pumps.

Insulin pumps are small computerized diabetes management devises, connected with cannula under the skin that is used to deliver a slow continuous level of insulin.The program can be controlled by the individual depends on the more or less requirement.

The increasing advancements and technology in glucose monitoring devices have result into smaller required blood volumes with improved accuracy.The ability to transfer data between the blood glucose (BG) meter and insulin delivery devices has been also improved.

The increasing advancements in blood glucose (BG) monitoring technology have resulted in improved accuracy, smaller required blood volumes, and the ability to transfer data between the BG meter and insulin delivery devices. For instance, in September 2016, the FDA announced their first automatically automatic glucose monitoring device, Medtronic's MiniMed 670G which is a hybrid closed looped system that provide suitable insulin doses in patient of age 14 years and above with diabetes type 1. Pen needles and syringes are the most commonly used device for injecting insulin to the diabetic patients. In addition, to reduce the injection site repetition for drug administration, montmd Inc. in April 2017 introduced a new a variant of SiteSmart colored pen needles to keep the injection site tissue healthy and promote better insulin adoption. Thus, the technological advancements coupled with increasing influx of new products into the market is expected to propel the growth of global pen needles market over the forecast years.

In 2018, the glucose monitoring devices segment held a largest market share of 54.2% of the diabetes care devices market, by product. The glucose monitoring devices is expected to dominate its market share in 2027 owing to the rise in the prevalence of the diabetes and presence of the several market players that offers technically advanced products. The testing strips segment among the glucose monitoring devices is anticipated to witness the fastest growth rate of 7.2% during the forecast period, 2019 to 2027 owing to the enormous usages in the glucose monitoring devices.

Homecare held a largest market share of 59.9% of the diabetes care devices market, by end user in 2018. This segment is also expected to dominate the market in 2027 owing to the rise in the demand for the glucose monitoring devices and insulin delivery devices. Increasing diabetic population, the ease of use, availability, and accessibility of insulin delivery devices has also increased the adoption of self-administration among patients is anticipated to grow at a steady rate during the forecast period. Also the homecare segment is also expected to grow at the fastest growth rate of 6.6% during the forecast period, 2019 to 2027.

Some of the major primary and secondary sources for diabetes care devices included in the report are, Associao de Diabetes Juvenil (ADJ), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), International Diabetes Federation(IDF) National Institute for Health and Care Excellence (NICE) and others.

Read the full report: https://www.reportlinker.com/p05794734/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Excerpt from:
The North America diabetes care devices market is expected to reach US$ 15,300.0 Mn in 2027 from US$ 8,936.5 Mn in 2018 - PRNewswire

Read More...

This World Diabetes Day, family is the focus – Gulf News

November 13th, 2019 6:54 am

There are 425 million diabetic people in the world and by 2045, that number is estimated to swell to 629 million. Image Credit:

As cheerless as it may sound, it is a fact that is diabetes is not just an individuals problem to tackle but the entire familys concern and the International Diabetes Federation has done well to theme this years World Diabetes Day on Family and Diabetes.

The overwhelming global concern for this disease, year after year, is not only warranted, it needs to be scaled to the highest levels of awareness because this is a health affliction that, rampant as it is, is predicted to get worse. Currently, there are 425 million diabetic people in the world and by 2045, that number is estimated to swell to 629 million, according to the Interactional Diabetes Federation (IDF).

The implications of such numbers are staggering in their import not just for individuals and families but also for governments who need to bear the cost of combating diabetes in their health care systems.

The discussions and urgencies about diabetes occupy two main streams: prevention and management, and both get equal play in the spotlight but there is, inarguably, a greater case to be made for the former.

The preventative aspect of diabetes is incalculable for the positive results it brings, by striking at the very root of the epidemic.

Experts stress on how important it is to continually maintain an environment of education, resources and implementation to help people stay informed on how diabetes can prevented, or having been diagnosed, be managed. But herein lies the rub. According to IDF, in 2013, of the 371 million people diagnosed with diabetes, nearly half of them did not know they had the condition.

This is precisely why this years theme is so powerful. Its not just the individual who needs to be aware of diabetes; families too need to stay educated on the genetic history of the disease, a hugely significant factor, and be focused on the importance of diet, exercise and stress management as pre-emptive factors because when diabetes strikes one or more members of a family, the lifestyle adaptations and discipline required to combat it are not individual responsibilities but a collective onus.

In the UAE, fortunately, there is much to be optimistic about. According to the National Health Survey in 2018, diabetes rates dropped to 11.8 per cent of the total population in 2017 from an alarming 19.3 per cent in 2013.

Let us all do our bit to keep this drop rate going.

View post:
This World Diabetes Day, family is the focus - Gulf News

Read More...

The Europe diabetes care devices market is expected to reach US$ 11,184.6 Mn in 2027 from US$ 6,853.3 Mn in 2018 – Yahoo Finance

November 13th, 2019 6:54 am

The market is estimated to grow with a CAGR of 5. 7% from 2019-2027. The growth of the diabetes care devices market is primarily attributed to the rising incidence of diabetes and rising adoption of insulin injection pens over traditional syringes & vials.

New York, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Diabetes Care Devices Market to 2027 - Regional Analysis and Forecasts by Product; End User; and Country" - https://www.reportlinker.com/p05794715/?utm_source=GNW However, availability of alternatives for drug delivery and reuse of pen needles are likely to pose a negative impact on the market growth.

On the other hand, increasing launch of GLP-1 analogues is likely to have a positive impact on the growth of the Europe diabetes care devices market in the coming years.Glucagon like Peptide-1 also known as GLP-1 is a hormone produced in the gut that is released in response to the food consumed by an individual.The peptide reduces the appetite of an individual and helps to secrete insulin in the body among obese patients.

In recent years, external injection of GLP-1 has been witnessing a significant traction due to increase in the number of doctor prescription for these hormones. The rising number of novel GLP-1 analogue launches is thus expected to indirectly provide opportunities for the manufacturers to develop therapy specific pen needles with incorporation of features such as bore size, length and material that is not reactive with the biologic.In 2018, the glucose monitoring devices segment held a largest market share of 53.9% of the diabetes care devices market, by product. The glucose monitoring devices is expected to dominate its market share in 2027 owing to the rise in the prevalence of the diabetes and presence of the several market players that offers technically advanced products. The testing strips segment among the glucose monitoring devices is anticipated to witness the fastest growth rate of 6.6% during the forecast period, 2019 to 2027 owing to the enormous usages in the glucose monitoring devices.In 2018, the homecare held a largest market share of 59.8% of the diabetes care devices market, by end user. This segment is also expected to dominate the market in 2027 owing to the rise in the demand for the glucose monitoring devices and insulin delivery devices. Increasing diabetic population, the ease of use, availability, and accessibility of insulin delivery devices has also increased the adoption of self-administration among patients is anticipated to grow at a steady rate during the forecast period. Also the homecare segment is also expected to grow at the fastest growth rate of 5.9% during the forecast period, 2019 to 2027.Some of the major primary and secondary sources for diabetes care devices included in the report are, Centers for Diabetes and Endocrinology (CDE), Public Health England (PHE), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), International Diabetes Federation (IDF) and others.Read the full report: https://www.reportlinker.com/p05794715/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Go here to read the rest:
The Europe diabetes care devices market is expected to reach US$ 11,184.6 Mn in 2027 from US$ 6,853.3 Mn in 2018 - Yahoo Finance

Read More...

Type 2 diabetes: Add this herb to your meals to lower blood sugar – Express

November 13th, 2019 6:54 am

One helpful to distinguish between low and high carbs is to look at the glycemic index, or GI, which measures how a carbohydrate-containing food raises blood glucose.

A food with a high GI raises blood glucose more than a food with a medium or low GI.

According to the American Diabetes Association, meal planning with the GI involves choosing foods that have a low or medium GI so if you are eating a food with a high GI, you can combine it with low GI foods to help balance the meal.

According to Diabetes UK, to stay on the safe side, opt for foods that are high in fibre and whole grains instead of refined carbs, such white bread.

Fibrous foods packed with wholegrain are better for your heart health and reducing our risk of certain types of cancers, notes the health site.

Read more here:
Type 2 diabetes: Add this herb to your meals to lower blood sugar - Express

Read More...

Morris Hospital hosting diabetes awareness event this month in Channahon – Morris Daily Herald

November 13th, 2019 6:54 am

In recognition of National Diabetes Awareness Month, Morris Hospital & Healthcare Centers is offering a free diabetes awareness event on Monday, Nov. 18, from 9 a.m. to noon at the Channahon Healthcare Center of Morris Hospital, 25259 Reed St., Channahon. The event is for anyone interested in getting screened for diabetes, as well as those who have already been diagnosed.

Free blood glucose screenings, hemoglobin A1C blood testing and retinal scans will be provided, along with diabetes education and an opportunity to meet and talk with Morris Hospitals endocrinology providers, Dr. Nuzhat Chalisa and Jennifer Greggain, N.P. Reservations for testing can be made by calling 815-467-0555, but walk-ins are also welcome.

The blood glucose screening is a finger-stick test that provides instant results indicating whether a person has diabetes or pre-diabetes, meaning the blood sugar level is higher than normal but not high enough to be classified as Type 2 diabetes. A 12-14 hour fast is recommended prior to the screening for accurate results.

The hemoglobin A1C (HbA1c) test is a simple blood test is being sponsored by the Morris Lions Club and measures a persons average blood sugar levels over the past three months, specifically identifying the amount of glucose attached to hemoglobin. This is a common test used to diagnose prediabetes and diabetes and is also used to measure how a person is managing their condition.

Trained nurses will conduct retinal scans to test for diabetic retinopathy, an eye condition that results in damage to the blood vessels of the retina due to diabetes. The scans taken at the event will then be sent to Ortiz Eye & Hearing Associates where they will be reviewed free of charge.

Diabetes is a chronic condition that affects the way the body metabolizes sugar. According to American Diabetes Association, in 2015, 30.3 million, or 9.4 percent of the American population had diabetes. Of those, 7.2 million were undiagnosed. While there is no cure for diabetes, proper management of the condition can often help avoid serious health complications including heart disease, blindness, kidney failure, and lower-extremity amputations.

As endocrinology providers, Dr. Chalisa and Jennifer Greggain specialize in diagnosing and treating individuals who have pre-diabetic and diabetic conditions. If you have any questions or concerns about diabetes or pre-diabetes, or if you would like to schedule an appointment, please call 815-467-0555 or visit http://www.morrishospital.org/endocrinology.

More here:
Morris Hospital hosting diabetes awareness event this month in Channahon - Morris Daily Herald

Read More...

Modern genetics will improve health and usher in designer children – The Economist

November 13th, 2019 6:54 am

SOMETIME NEXT year, if all goes to plan, a gay male couple in California will have a child. The child in question will have been conceived by in vitro fertilisation. In this case a group of eggs from a female donor are now being fertilised by sperm from both fathers (half from one, half from the other). Of the resulting embryos, the couple will choose one to be implanted in a surrogate mother. An uplifting tale of the times, then, but hardly a newsworthy event. Except that it is.

Where the story becomes newsworthy is around the word choose. For the parents, in conjunction with a firm called Genomic Prediction, will pick the lucky embryo based on a genetically estimated risk of disease. Such pre-implantation testing is already used in some places, in cases where there is a chance of parents passing on a condition, such as Tay-Sachs disease, that is caused by a single faulty gene. Genomic Prediction is, however, offering something more wide-ranging. It is screening embryos for almost 1m single-nucleotide polymorphisms (SNPs). These are places where individual genomes routinely differ from one another at the level of an individual genetic letter. Individual SNP differences between people rarely have much effect. But add them up and they can raise or lower by quite a lot the likelihood of someone suffering a particular disease. Generate several embryos and SNP-test them, then, and you can pick out those that you think will grow up to be the healthiest.

Upgrade your inbox and get our Daily Dispatch and Editor's Picks.

Much fuss was made last year about a researcher in China, He Jiankui, who edited the genomes of two human embryos in order to try, he claimed, to make them immune to infection by HIV, the virus that causes AIDS. What Genomic Prediction proposes is different. No editing is involved. There is thus no risk of harming a child by putting it through a risky experimental procedure. Whether Genomic Predictions particular technique will actually deliver super-healthy children remains to be seen. The principle seems plausible, though. History may therefore look back on this moment as the true beginning of designer babies. And the tool that has made that possible is called GWAS.

GWAS stands for genome-wide association study. It is the endpoint of a historical process that began in the mid-19th century with Gregor Mendel, a Moravian abbot and amateur botanist. Mendel worked out the first set of rules of heredity. This led to the idea of a gene. And that, when allied with the discovery that the material of heredity is a chemical called DNA, which encodes genetic information in the order of its component units, known as nucleotides, led to the idea of a gene being a particular piece of DNA that carries in its nucleotides the blueprint of a particular protein. This protein goes on to contribute, in combination with environmental effects such as nutrition, to a particular bodily or behavioural characteristic, known as a phenotypic trait.

Since the 1950s, researchers have tried to quantify the relative contributions of genes and the environment to such traits. Mostly, this is in the context of disease. But behavioural characteristics, personality and cognitive ability have also been matters of interest. GWAs expands this process by looking not just at the effects of individual genes, but across the whole genomefor protein-coding genes make up only about 2% of a persons DNA.

Comparisons, over several generations of a family, of the prevalence of a particular trait yield estimates of its heritabilitya measure of how well individual genetic differences account for variations in that trait in a given population. A heritability of 100% indicates that any differences in a trait between individuals in that population are accounted for solely by genetic factors, while 0% suggests the environment alone is responsible. The phrase given population is important. Some populations may be exposed to relevant environmental variables unknown to others. Conversely, genetic factors present in one group (better response to oxygen scarcity in those evolved to live at high altitude, for example) may be absent in another.

An analysis published in 2015 of more than 2,700 studies of heritability shows that its average value, for all traits looked into in those studies, is about 50%. That includes physical traits like susceptibility to heart disease (44%) and eye disorders (71%), and mental ones, including higher-level cognitive functions (47%) such as problem-solving and abstract thought.

Other, less obvious traits are heritable, too. The amount of time a child spends watching television was assumed for many years to have a heritability close to zero. In 1990, however, a study led by Robert Plomin, now at Kings College, London, compared the habits of adopted children with those of their birth mothers. It found television-watching has a heritability of about 45%. Similar surprisingly heritable traits include a childs tendency to be bullied at school (more than 70%) or to be accident-prone (51%). Even someones likelihood of being religious (30-40%) or of getting divorced (13%) is heritable.

In 1989 James Watson, the first head of the Human Genome Project, summarised the mood of many by declaring that We used to think our fate was in our stars. Now we know, in large measure, our fate is in our genes. There was hope then that the genome project would locate those genes. No one was naive enough to think that there existed, say, such a thing as a gene for television-watching. But it was reasonable to believe that there might be a handful of genes which combined to encourage television-watching indirectly. More important, there was an expectation that the heritable causes of things like heart disease might be pinned down to such genetic handfuls. These might then be investigated as drug targets. To everyones frustration, though, few such genes revealed themselves. And in most cases the contributions they made to a conditions heritability were small. Where, then, was the missing heritability?

With hindsight, the answer was obvious. The number of variants that play a role in disease risk is far higher than Mendel-blinded researchers had imagined. Though human beings are genetically more than 99.9% alike, they have 6bn genetic letters in their genomes. This is where the SNPs are hidden, for a diversity of less than 0.1% still leaves room for millions of them. And when SNPs contributions are combined, their effects can be significant. For height, for example, the number of relevant SNPs is reckoned to be about 100,000each adding or subtracting, on average, 0.14mm to or from a persons adult stature. Furthermore, most of these SNPs are in parts of the genome that do not encode proteins at all. Rather, they regulate the activities of other genes and often have no obvious connection to the trait in question.

To be fair, it was mainly human geneticists who were captivated by the simple Mendelian model of single genes with big effects. According to Peter Visscher of the University of Queensland, Australia, many plant and animal scientists knew of traits genetic complexity long before the Human Genome Project started. But they were more interested in breeding better crops or livestock than in understanding the biology behind such complexity.

Dr Visscher was one of the first to realise that human studies would need to recruit more participants and screen for many thousands more SNPs if they were to capture in full the genetic components of most traits. In 2007 he and his colleagues used models to show that for a condition with a prevalence of 10% in the general population, approximately 10,000 volunteers are required to identify the SNPs marking the 5% of those at highest risk of developing that condition. Earlier studies, often with just a few hundred participants, had simply not been powerful enough to see what was going on. And thus was GWAS born.

Ideally, a GWAS would obtain a full sequence of the genome of every participating individual. However, even though the cost of such sequences has fallen dramatically since the completion of the genome project, to about $1,000 a shot, this would still be prohibitively expensive. Instead, researchers use devices called SNP arrays. These detect hundreds of thousands of the most common SNPs for a price of $50 or so.

A combination of SNP arrays, larger samples of volunteers and better computing methods means it is now possible to find millions of variants that contribute to a trait. An individuals score from these variants, known as his polygenic score, can then be calculated by adding up their contributions to give, for example, his risk of developing a particular disease in later life.

Another advance has been a change in the way volunteers are recruited. Institutions called biobanks have come into existence. These hold both tissue samples from, and a range of medical and other data about, large numbers of people who have agreed to make those data available to researchers who meet the criteria employed by the bank in question.

Among the largest of these repositories is the UK Biobank, in Britain. This has 500,000 depositors. One study that drew on it, published in 2018 by Sekar Kathiresan of the Massachusetts General Hospital in Boston and his colleagues, worked out polygenic risk scores for five diseases, including coronary heart disease and type 2 diabetes. By totting up scores from over 6m genetic variants, they were able to elucidate SNP patterns that identify those who are at a threefold higher risk or worse than the general British population of developing one of these diseases. For heart disease, 8% of the population are at such risk. For type 2 diabetes, 3.5%.

Nasim Mavaddat of the University of Cambridge and her colleagues have similarly calculated polygenic risk scores for breast cancer. These showed that a British womans average ten-year risk of developing breast cancer at the age of 47 (the earliest that Englands National Health Service begins screening for the disease) is 2.6%. The study also found that the 19% of women who had the highest risk scores reached this level of risk by the age of 40. Conversely, the 10% at lowest risk did not cross the threshold until they were 80.

Using these and similar studies, it is possible to draw up lifetime risk profiles for various medical conditions. A British firm called Genomics has done that for 16 diseases (see chart). This will help screening programmes to triage who they screen, by offering their services earlier to those at high risk of developing a condition early in their lives. It will also permit the dispensing of risk-appropriate advice about diet and exercise to those who need it most, and the early offering to those who might benefit from them of things like statins and antihypertensive drugs. In light of all this Englands National Health Service announced in July that 5m healthy Britons would be offered free gene tests.

A third study that drew on the UK Biobank is rather different. It was published in October and demonstrated the power of GWAS to reach beyond non-medical matters. It examined patterns of internal migration in Britain, and showed that there has been an outward migration from former coalmining areas of people with SNP patterns associated with high educational attainmentprecisely the sorts of individuals economically deprived places can least afford to lose.

Educational attainment also demonstrates how heritability varies with environment. In Norway, for example, heritability of educational attainment increased after the second world war as access to education widened. Since all children now had more or less the same opportunities at school, environmental variation was largely ironed out and the effects of genetic differences consequently exaggerated.

Both of these examples foreshadow how the sort of genetics made possible by GWAS can have political consequences. The implication of the internal-migration study is that the geographically left-behind are dimmer, on average, than the leavers. The implication of the Norwegian study might likewise be seen by some as suggesting that those who have done well at school and thus snagged the best (and best-paid) jobs are part of a genetic elite that deserves its success, rather than being the lucky winners of a genetic lottery.

And that is just within a country. Start comparing people from different parts of the world and you enter a real minefield. Because most of the genetic data now available come from populations of European ancestry, their predictive power is poorer for people from elsewhere. Alicia Martin of the Broad Institute in Massachusetts and her colleagues scored West Africans for height based on SNPs drawn from studies on European or European-derived populations. The scores predicted that West Africans should be shorter than Europeans. Actually, they are not.

As more people of non-European ancestry are sequenced, these problems may abate. But if group-based differences emerge or persist in the face of better data, that would be cause for concern. Differences between groups in things like height are rarely cause for prejudice beyond a jocular level. For something like educational attainment, by contrast, there is a risk that politically motivated groups would try to exploit any differences found to support dubious theories of racial superiority.

To some historians, this looks horribly familiar. They fear that the old spectre of eugenics risks rising in a new guise. As Nathaniel Comfort of Johns Hopkins University, in Baltimore, observes, The IQ test was invented in order to identify students who needed extra help in school. But within about a decade, it was being used as a tool to weed out the so-called feebleminded, not just from school but from the gene pool. Such fears of genetic stratification would become particularly acute if polygenic scores were applied to embryos for the purpose of selecting which to implant during IVFas Genomic Prediction is just about to do.

Genomic Prediction and a second firm, MyOme (which is not yet accepting customers), claim to be able to build up an accurate picture of an embryos genome. That is tricky because the sequencing has to be carried out using the tiny quantities of DNA in a few cells taken from that embryo. A sequence so obtained would normally be full of errors. The two companies say they can deal with this by comparing embryonic sequences with those of the biological parents. All of the DNA in the embryo has come from one or other parent, so blocks of embryonic DNA can be matched to well-established sequences from their parental progenitors and an accurate embryonic sequence established. That makes working out the embryos SNP pattern possible.

Genomic Prediction thus says it is able to offer couples undergoing IVF a polygenic risk score for each embryo for a variety of diseases including type 1 diabetes, type 2 diabetes, breast cancer, testicular cancer, prostate cancer, basal-cell carcinoma, malignant melanoma, heart attack, atrial fibrillation, coronary artery disease, hypertension and high cholesterol. At the moment it does not offer scores for non-medical traits like height or educational attainment. But there is nothing to prevent it from doing so should it so wish.

Even for medically relevant scores, however, some worry about this approach. One concern is pleiotropythe phenomenon of the same piece of DNA influencing several apparently unrelated traits. Choosing an embryo with a low risk of heart disease might accidentally give it, say, a higher chance of developing epilepsy. Single-mindedly maximising scores for positive traits like intelligence or height may therefore increase the risk of genetic disorders.

Stephen Hsu of Michigan State University, one of Genomic Predictions founders, acknowledges the theoretical risk of this, but argues that serious pleiotropic effects are unlikely. If you looked at a bunch of kids with IQs of, say, 160 or 170, he says, I doubt youd find much seriously wrong with them. Theyd just be a bunch of geeks. Dr Hsu, who in 2014 predicted that reproductive technologies would soon be used to select for more intelligent offspring, estimates that an IQ gain of between 10 and 15 points would be possible if couples were allowed to choose between ten embryos. He also thinks that further gains would probably accumulate if people selected in this way went on to select their own offspring on the basis of intelligence.

This is plausible. Before 2008, when the first SNP chips for cattle became available, the annual milk yield of dairy cows in America had been increasing at about 50kg per year. After six years of chip-based polygenic selection, the rate of increase had doubled to more than 100kg per year. This suggests the technique is powerfulin cattle at least. Despite Dr Hsus optimism, however, pleiotropism has reared its head in these animals. They have become less fertile and have weaker immune systems.

In the end, then, it is generally a good idea to remember that human beings have already been optimised by a powerful agent called natural selection. Trade-offs between different pieces of physiology, even in domestic animals, will have been forged in the crucible of evolution and will generally be optimal, or close to it. Genetic tinkering may sometimes improve things. But by no means always.

Read more:
Modern genetics will improve health and usher in designer children - The Economist

Read More...

GenomeSmart and NorthBay Healthcare Launch Pilot to Improve Access to Genetic Testing with GenomeBrain – Business Wire

November 13th, 2019 6:54 am

LOS ALTOS, Calif. & FAIRFIELD, Calif.--(BUSINESS WIRE)--GenomeSmart, a Silicon Valley-based company delivering the first and only AI-powered genetic risk assessment and test recommendation platform to improve access to genetic testing, announced today that NorthBay Healthcare, an independent nonprofit health system in Northern California, has selected the GenomeBrain Platform for a pilot program planned to improve the routine use of genetic testing in patient care.

Weve looked at many options to support our providers but the GenomeBrain Platform offered us more of the critical features we wanted plus gave us the ability to customize to our needs, said Lori Muir, Oncology Services Director. NorthBay Healthcare is dedicated to delivering best-in-class oncology care to the patients we serve and we believe ensuring easy access to genetic testing is a critical part of those vital services. Were looking forward to working with GenomeSmart to support our providers in better identifying patients for testing, efficiently tracking available tests, and speeding access to hereditary risk results.

"This approach to screening patients will make it much easier for people to understand why and when genetic testing can impact their healthcare decisions. We are bridging an educational gap that, until now, has made access to genetic testing difficult. Our patients will no longer wonder if genetic testing is right for themthey will know before they even come in to see me," added Karen Vikstrom, MS, Certified Genetic Counselor, NorthBay Healthcare.

The NorthBay Healthcare pilot program will be completed in conjunction with the NorthBay Breast Cancer Program. The pilot is designed to ensure patients with breast cancer receive treatment based on genetic risk and to scale testing into routine care for healthy women and men to identify potential hereditary risks, ensuring appropriate access to screening and care programs. The GenomeBrain Platform will be incorporated into the current patient workflow and evaluated for effectiveness and ease of use.

The GenomeBrain Platform is accessed online through a mobile phone, tablet, or desktop device. The simplified experience first builds a patient profile, including their relevant personal medical history, family medical history, ethnicity and age, and then instantly matches them to the appropriate genetic tests based on the latest medical guidelines for genetic testing. GenomeBrain uses AI to ingest large amounts of data from patient history, genetic tests available on the market, and medical guidelines to simplify a cumbersome manual process that usually takes days to less than ten minutes on average.

Were thrilled to be partnering with NorthBay Healthcare on this important initiative, said Sanjay Sathe, CEO and co-founder, GenomeSmart. The NorthBay teams agility and interest in innovative approaches to care make them the ideal partner for us. They are able to implement efforts quickly and provide personalized care to their local community that rivals many larger urban-based institutions, all for the betterment of their patients.

About GenomeSmart

GenomeSmart is on a mission to make genetic testing available to everyone. In May 2019, the company launched GenomeBrain, the first and only AI-powered genetic risk assessment and test recommendation platform that matches and identifies people who could benefit from genetic testing. The affordable GenomeBrain Platform multi-functional solution is available to help genetic counselors, physicians, hospital systems, genetic testing labs, insurance companies, and corporations improve the effective use of genetic testing to save lives, improve quality and reduce costs of healthcare.

About NorthBay Healthcare

NorthBay Healthcare opened its first hospital in 1960 and remains Solano Countys only locally based, locally managed nonprofit health system. NorthBay Medical Center in Fairfield and NorthBay VacaValley Hospital in Vacaville offer 24-hour emergency care, intensive care, and sophisticated surgical and diagnostic services. NorthBay Cancer Center, located on the Vacaville campus, opened more than 30 years ago. NorthBay Healthcare is a member of the Mayo Clinic Care Network, giving its patients access to world-renowned physicians and Mayo Clinic research.

See more here:
GenomeSmart and NorthBay Healthcare Launch Pilot to Improve Access to Genetic Testing with GenomeBrain - Business Wire

Read More...

Secret Shopper: What supplements are best to boost immunity? – New Hope Network

November 13th, 2019 6:53 am

NFM Secret Shopper: Im confused about whats best to boost my immunity. Is it zinc, vitamin C, vitamin D, elderberry or something else?

Retailer: Any of those can help with immunity, but it depends on when you take them. Vitamin C is good for when you already have a cold, but if you eat your fruits and veggies, you probably dont need to take a vitamin C supplement all the time. Same with zinc and elderberry. But vitamin D is a supplement you might need every day, depending on your levels.

NFM: That makes sense. Any other supplements youd recommend, especially for cold and flu season?

Retailer: Garlic is popular and seems to work pretty well for immunity.

Our expert educator: Yufang Lin, M.D., of the Cleveland Clinics Center for Integrative and Lifestyle Medicine

Immunity is very complex. As an integrative practitioner, I look at the whole picture, so the first things I suggest are getting enough sleep, hydrating well and eating healthy. As for specific foods that boost immunity, garlic and ginger are both antimicrobial, antifungal and antiviral. You can use them in your day-to-day cooking, but if you are getting sick, definitely step up your intake, whether through food or supplements. Ginger, which is also anti-inflammatory, can also be made into tea.

There is data showing that both vitamin C and zinc support the immune system when you are sick. They are particularly useful in the first few days of illness, as they can reduce the duration and severity. But use these supplements only as needed, not on a long-term basis.

Elderberry is a diuretic, so if you are running a fever, it can help you sweat it out. Another supplement, echinacea, revs up the immune system, so it is great for fighting off a cold or even for the early stages of the flu. The problem with echinacea is it can stimulate the immune system too much, which is bad if you have an autoimmune disease. But for most people, it can be very helpful, but take it only for three to five days.

Vitamin D is a hormone so it generally has many benefitsfor mood, bone health and immune support. But it is more for day-to-day care, not to start taking once you get sick.

Read the original here:
Secret Shopper: What supplements are best to boost immunity? - New Hope Network

Read More...

This Is Your Body On The Flu – HuffPost

November 13th, 2019 6:53 am

Tis the season for turkey trots, Black Friday sales and fighting over the last piece of pumpkin pie. Oh, and the flu.

According to the U.S. Centers for Disease Control and Prevention, 3% to 11% of people in the U.S. have to deal with the flu each year, with an average of 8% getting sick. And while the flu vaccine is a must, it still only reduces your flu risk by 40% to 60%, meaning its not a complete safeguard depending on your health, age and the type of flu virus you contract. (If you do contract the flu after youve gotten a flu shot, the vaccine will lessen the severity of symptoms and help prevent against flu-related complications like pneumonia. So its still important to get it.)

Here, flu experts share what happens once youre exposed to the flu including why it triggers some of those unpleasant symptoms like fevers, aches and chills. Read on to learn, plus get some guidance on how to stay as protected as possible this flu season.

First, the flu has to find a way to get into your body

Simply being in the house with someone who has the flu wont get you sick, but it can definitely increase your risk factor if youre not practicing proper hand-washing hygiene.

The virus has to find a way to get into either your nose or mouth, said Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security. Its usually transmitted from person to person through coughing, sneezing, or mucus or saliva that might be on someones hands. It can also be transmitted from common surfaces that people may touch. They may have wiped their nose and then touched their hands before putting it on a surface or may have sneezed on the surface.

Your eyes and ears may be access sites as well, but Adalja said these are far less common entry points, so make sure you wash your hands often and well during flu season to prevent the virus from infecting you to begin with.

You wont have symptoms right away once the virus enters your system

Once the virus enters your nose or mouth through direct contact (like being sneezed on, yuck) or indirect (such as using a towel shortly after an infected person has previously used it) the virus will make its way to your immune system, but this wont happen immediately.

Once the flu gets into your body, it will set up shop and cause the same infection in you, said Aaron Glatt, chairman of infectious diseases and hospital epidemiologist at Mount Sinai South Nassau in Hewlett, New York. The incubation period is about one to four days. On average two days, but it is still a highly contagious disease during this time.

This means that you could be asymptomatic for a day or two but very much able to spread the flu to others without even knowing it.

torwai via Getty Images

Once the flu settles in, its heading for your cells

Specifically, the virus goes to your respiratory epithelial cells, which line your respiratory tract.

The virus binds to sialic acids that are on these cells, and these sialic acids function as receptors to help the cells signal and communicate to each other, Adalja explained.

The virus is able to bind to these cells thanks to a protein called hemagglutinin (which is what the H stands for in flu strains like H1N1). With the help of this protein, the virus attaches itself to the cell and then gets inside the cell, which will send an alarm to your immune system.

Some flu symptoms are from an immune system response

After your immune system figures out theres a virus inside the body, it will go into overdrive to get it out as quickly as possible.

As part of that, the immune response will start to ramp up some of the symptoms that you feel. Fevers, muscle aches and pains are the result of certain chemicals being secreted by the immune system in order to fight that virus off, Adalja said, adding that a quarter of people with the flu have no symptoms. This doesnt mean your immune system isnt working, its just how you clinically present the virus.

Basically, your body becomes a battlefield when you have the flu and the reason you feel so terrible is from the war between the pathogen and your immune system, Adalja said.

Prostock-Studio via Getty Images

The average shelf life of the virus is about a week

Most healthy people have self-limited disease, Glatt said. They get sick for a couple days, or some people dont get very sick at all. Other people get a mild illness or more moderate illness for a couple of days or a week or two at most.

The standard run-of-the-mill flu in a healthy person typically doesnt require treatment but certain groups are at a higher risk of developing complications from the flu including pregnant women, those with certain underlying diseases, children less than 12 months old, or adults over the age of 65.

Glatt said for these groups especially, its important to make an appointment with a physician as soon as flu symptoms come on. Theyll be able to prescribe an appropriate antiviral medication to help relieve symptoms and clear the virus out of your body as fast as possible. (This is also good general advice, as doctors can prescribe medications like Tamiflu to help reduce the severity and length of the illness.)

Other than that, get lots of rest, drink fluids and monitor your symptoms. While you may be miserable for a few days, your body will fight the flu the best it can.

Read this article:
This Is Your Body On The Flu - HuffPost

Read More...

Aspergillus Endangers Children at Hospital for Second Time This Year – Infection Control Today

November 13th, 2019 6:53 am

The presence of the fungusAspergillushas forced theclosingof 11 operating rooms at Seattle Childrens Hospital, marking the second such closure in a year. All 14 of the hospitals operating rooms will be closed later in the week, said hospital spokeswoman Kathryn Mueller.

"On November 10, routine air test results revealed the presence ofAspergillusin the air in 3 of our operating rooms and 2 procedural areas," Mueller said. "The rooms in whichAspergilluswas detected have been closed. We are also investigating 2 new potentialAspergillussurgical site infections."

The hospital has had to postpone some surgeries and move others to different hospitals.Aspergillusis a fungus whose spores are present in the air and can cause illnesses in people with weakened immune systems, damaged lungs, and asthma. Infections caused byAspergillusincludeinvasive aspergillosis,ABPACPA, and aspergilloma.

Seattle Childrens Hospital says that the fungus has infected at least 1 patient, and possibly 2. This is the second time the fungus has been discovered in the hospitals operating rooms. The previousAspergillusoutbreak inMayled to at least 5 infections and 1 death.

Hospital officials blame the presence ofAspergillusin the operating rooms on deficiencies in ventilation and purification systems.

AnarticleinHPAC Engineeringnotes that hospitals consume much more energy than buildings and facilities in other industries of similar size. More energy is therefore needed to ventilate and purify the air.

Healthcare facilities that may not be properly ventilated, designed, or controlled can lead to the spread of airborne pathogens throughout the facility, according to the article. Hospital patients who have compromised immune systems and are more susceptible to infection will likely be infected and can spread pathogens to the rest of the hospital.

The article, which ran last year, also focused on the importance of a good filtering system in facilities and touts the benefits of bipolar ionization systems. They create negative and positive ions which then react with oxygen and water vapor within the air stream, creating free radicals. These free radicals in turn create chemical changes, which can damage viruses, bacteria and other microorganisms that often cause infections within a hospital. Even with this kind of system, filter media is still necessary to remove larger particles from the air stream. A filter media is anything in a filter that changes the quality of whats being filtered.

The Infectious Diseases Society of America (IDSA) recommends that the response toAspergillusinfection should involve submitting tissue and fluid specimens for histopathologic, cytologic, and culture examination to diagnose invasive aspergillosis. However, molecular techniques, such as DNA sequencing, should be used to identifyAspergillusspecies in cases that involve either isolates with atypical growth or concern for resistance, the IDSA recommends.

Astudythis year inAntimicrobial Resistance & Infection Controlnoted that the construction work at hospitalswhich seems to be happeningmore and morecan help breed invasive aspergillosis (IA)infection.

Investigators with the University of Ulsan College of Medicine in South Korea, wrote: Airborne fungal spore levels tended to be higher during the period with heavier construction works involving demolition and excavation, during which the incidence of IA was significantly higher as well.

They argued that airborne fungal spore levelsshould be monitored when constructions taking place in hospitals with patients who have compromised immune systems.

Go here to see the original:
Aspergillus Endangers Children at Hospital for Second Time This Year - Infection Control Today

Read More...

Kirin’s functional food brand expands to Vietnam with immunity-boosting probiotic drink – BeverageDaily.com

November 13th, 2019 6:53 am

The iMUSE yoghurt & lemon flavoured drink contains lactococcus lactis strain plasma which the firm claims to have immune functionality to fight infectious disease in the country.

The drink contains 100 billion lactococcus lactis plasma, which is a lactic acid bacteria and an ingredient used exclusively by the Kirin Group.

According to Interfood Shareholding Company (Kirin Holdings subsidiary), general manager of marketing, Takeshi Fukushima: The Health and well-being trend is emerging in Vietnam. More people are taking up supplements.

The firm said while Vietnamese were highly health-conscious and spending more money on nutritional healthcare products, it said the spread of infectious diseases like dengue fever and hepatitis in the country was becoming a problem.

Hence, the yoghurt & lemon flavoured drink could propose new health value of drinking soft drinks to manage ones health in an effort to help the country solve the social problem, Kirin said.

Fukushima said the drink was able to enhance the anti-viral immune system and maintain overall health.

Its other benefits include reducing the risks of cold and flu symptoms, enhance health of skin from the inside, and reduce symptoms of fatigue in physical activity.

The Kirin Group is currently conducting research especially in the area of infectious diseases, to help those vulnerable, and contribute to achieving the United Nations Sustainable Development Goals (SDGs).

Fukushima told NutraIngredients-Asia, the first month of sales in Vietnam achieved 250% versus target.

It retails for 13,000VND (US$0.50) per 280ml at supermarkets, convenience stores, school cafeterias, and school stores in Vietnam.

Kirin Group had only promoted the iMUSE brand containing lactococcus lactis strain plasma mainly in Japan.

The drink is the first product sold overseas under the iMUSE brand.

This move is part of Kirins business strategy to expand the iMUSE brand in South East Asia.

Vietnam was selected for its population of 94 million, and 7.1% annual real-term growth in gross domestic product (GDP).

Original post:
Kirin's functional food brand expands to Vietnam with immunity-boosting probiotic drink - BeverageDaily.com

Read More...

The gut may be the ticket to reducing chemo’s side effects – The Ohio State University News

November 13th, 2019 6:53 am

In a new study, scientists observed several simultaneous reactions in mice given a common chemotherapy drug: Their gut bacteria and tissue changed, their blood and brains showed signs of inflammation, and their behaviors suggested they were fatigued and cognitively impaired.

The research is the first to show these combined events in the context of chemotherapy, and opens the door to the possibility that regulating gut bacteria could not only calm chemo side effects like nausea and diarrhea, but also potentially lessen the memory and concentration problems many cancer survivors report.

More research is needed to further understand how the chemo-modified gut influences the brain in a way that can have an impact on behavior. The same lab at The Ohio State University is continuing mouse studies to test the relationship and running a parallel clinical trial in breast cancer patients.

This is the first time anyone has even looked to see if theres a link between the gut symptoms and the brain symptoms associated with chemotherapy, said lead author Leah Pyter, assistant professor ofpsychiatry and behavioral healthand an investigator in theInstitute for Behavioral Medicine Researchat Ohio State. There have been studies in humans that indicate that chemo alters microbes in the gut, and our study in mice had similar results.

We were able to see that there are brain changes at the same time as the gut changes. We also looked at inflammation, and yes, there are all these changes happening at the same time. So there are correlations, and now were looking into causality.

The study is published today (Nov. 11) in the journal Scientific Reports.

For this study, female mice received six injections of the chemotherapy drug paclitaxel and a control group of mice received placebo injections. Compared to the controls, the treated mice lost weight and showed signs of fatigue, and their performance on tests suggested they had memory loss.

The treated animals guts, blood and brains were also affected in ways not seen in the control mice. The mix of bacteria in the gut microbiome changed, and the tissue lining the colon became abnormally extended. Specific proteins were present in circulating blood and the brain along with activated immune cells in the brain all indicating the immune system was busy producing a total-body inflammatory response.

The sequence of events suggested all these physiological changes were related: The gut was showing signs of permeability, meaning bits of bacteria could slip out of tight junctions in the intestine, an event that triggers an immune system attack. When the brain detects through the blood and neural signals that the bodys immune system is activated, the brain responds in kind with its own inflammation. And brain inflammation is the culprit behind the mental fog symptoms known as chemo brain.

Pyters team tested all the data for associations and found the strongest correlations between changes in the gut microbes and in the colon lining and the activation of immune cells called microglia in the brain.

Every time chemo reduced bacteria in the gut, that reduction was correlated with these cells in the brain, said Pyter, also a member of theCancer Control Research Program at Ohio States Comprehensive Cancer Center.

This suggests chemotherapy is affecting the microbes in the gut and affecting the lining of the gut, and both of those changes cause inflammation in the periphery, which creates signals that promote inflammation in the brain, she said. Thats how we get the brain involvement through the immune system. And inflammation in the brain leads to sickness behaviors like fatigue and weight loss, as well as cognitive impairment.

Confirmation of these connections could lead to interventions for cancer patients either dietary strategies such as probiotics or prebiotics or possibly fecal transplantation to promote bacteria and conditions in the gut that protect the brain from inflammation, which should reduce chemo brain symptoms.

This is just the first step of trying to broach the concept to see if these harsh gut effects of chemo have anything to do with chemo brain. It looks like it has potential, Pyter said.

This work was supported by The Ohio State University Wexner Medical Center and grants from the National Institutes of Health.

Kelley Jordan and Browning Haynes of Ohio State and Brett Loman and Michael Bailey of Nationwide Childrens Hospital were study co-authors.

Read more here:
The gut may be the ticket to reducing chemo's side effects - The Ohio State University News

Read More...

OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO(TM) KEYNOTE Studies Evaluating Patients with Advanced Solid…

November 13th, 2019 6:53 am

SAN DIEGO and PENNINGTON, N.J., Nov. 12, 2019 /PRNewswire/ --OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced outcomes from a safety and biomarker analysis on its lead product candidate, TAVO, at theSociety for Immunotherapy of Cancer(SITC) 34th Annual Meeting. Outcomes demonstrated treatment-related changes in key immune biomarkers coinciding with clinical outcomes across both KEYNOTE-695 and KEYNOTE-890 trials of TAVO in combination with KEYTRUDA (pembrolizumab).

In the poster, which was presented on November 9, 2019, investigators noted that following TAVO administration, increased tumor infiltrating CD8+ T-cells were consistent with tumor shrinkage in anti-PD-1 antibody refractory melanoma and chemotherapy refractory metastatic triple negative breast cancer (mTNBC). The interim analysis also highlighted the systemic immune effects of TAVO, including increases in the frequencies of circulating memory T cells and reduced frequencies of circulating immuno-suppressive PMN-MDSC cells in predominately responding patients across both indications. Additionally, a broad safety analysis of over 200 patients treated with TAVO in multiple cancer indications across several clinical trials including TAVO as a monotherapy as well as in combination with KEYTRUDA was reported. There were no Grade 4 or 5 treatment-related adverse events reported and only 7.9% of patients experienced Grade 3 treatment-related adverse events across all TAVO studies, underscoring a predictable and consistently well-tolerated safety profile.

OncoSec is currently evaluating TAVO in combination with KEYTRUDA in a pivotal trial for Stage III/VI anti-PD1 checkpoint resistant metastatic melanoma and a phase 2 trial for late stage chemo-refractory metastatic TNBC, both KEYNOTE-designated studies. The immune data presented at SITC represented those patients for whom pre- and post-treatment blood and tumor samples were obtained in these ongoing KEYNOTE studies.

"The data presented at SITC were consistent with earlier published data showing that the well-established indicators of immune response are present in the blood and tumor tissue post-treatment and that the presence of these immune signatures continues to be associated with clinical response," said Daniel J. O'Connor, CEO of OncoSec. "Further, with more than 200 TAVO-treated patients, we clearly see that these powerful clinical responses are delivered with an excellent safety profile as both a monotherapy and importantly, in combination with anti-PD-1 therapy."

About OncoSec Medical IncorporatedOncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec has built a deep and diverse clinical pipeline utilizing its primary technology, TAVO(tavokinogene telseplasmid) as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non- responders. In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visitwww.oncosec.com.

TAVOis a registered trademark of OncoSec Medical Incorporated.

KEYTRUDAis a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Forward Looking StatementsSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the status, progress and results of our clinical programs; our ability to obtain regulatory approvals for, and the level of market opportunity for our product candidates; our business plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements or transactions; expectations regarding our liquidity and performance, including expense levels, sources of capital and ability to maintain operations as a going concern; the competitive landscape of our industry; and general market, economic and political conditions; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Company Contact:Gem HopkinsHead of Corporate Communications858-210-7334ghopkins@Oncosec.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-presents-immunological-data-associated-with-positive-tumor-response-from-tavo-keynote-studies-evaluating-patients-with-advanced-solid-tumors-at-the-society-for-immunotherapy-of-cancer-sitc-34th-annual-meeting-300956116.html

SOURCE OncoSec Medical Incorporated

See the original post here:
OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO(TM) KEYNOTE Studies Evaluating Patients with Advanced Solid...

Read More...

The Ebola Vaccine Is Now Officially Here With Approval In Europe – Forbes

November 13th, 2019 6:53 am

A nurse prepares a vaccine against Ebola in Goma on August 7, 2019. (Photo by AUGUSTIN WAMENYA/AFP ... [+] via Getty Images)

Its official. We now have a real Ebola vaccine. Not a kind-of-almost-sort-of-there vaccine. Not an experimental-use vaccine. Not a vaccine just for macaques. No, this is a vaccine that the European Commission has just approved for use in humans, the first of its kind.

According to todays announcement, the European Commission has granted Merck Sharp and Dohme B.V. marketing authorization in Europe for their Ebola vaccine, named Ervebo. The approval came not too long after the European Medicines Agency (EMA) had recommended approval in mid-October.

This is big. Actually, its big times big plus big. Having a vaccine to protect against the Ebola virus is a game changer. The Ebola virus, in technical terms, really sucks. It is a nasty virus that can cause a severe and deadly hemorrhagic fever. Fever means fever as in body temperature rising. And hemorrhagic means bleeding as in blood leaking out of blood vessels inside your body, in your skin, and potentially in your eyes, nose, ears, mouth, and rectum.

05 September 2019, Congo, Goma: Signposts on the premises of the UN peace mission "Monusco" point ... [+] out symptoms, danger of infection and course of disease of Ebola. (Photo by Kay Nietfeld/picture alliance via Getty Images)

How can the virus wreak such havoc? The virus is a sneaker sucker. It first targets cells that serve as your immune systems first line of defense. This is a bit like the Oceans 11 crew taking out the surveillance system first when trying to rob Terry Benedicts casino. As a result, your immune system cannot even recognize that something is amiss. Eventually, macrophages, which are your bodys cookie monster-like protectors, gobble up the viruses. This then triggers your macrophages to do the wrong thing. Your macrophages release proteins that initiate a cascade of events that cause the formation of small blood clots, inflammation, and leaks in your blood vessels throughout your body. This leads to the unhappy combination of you losing blood and blood flow to your organs being blocked, which starves your organs of oxygen. This process is what ends up killing up to 90% of those infected by the virus, according to the World Health Organization (WHO) Africa Region Office.

If this sounds horrible, it is. Ebola infections can be costly too. As our PHICOR teams study published in the Journal of Pathogens and Global Health showed, the cost of each case can range from several hundred dollars (if you fully recover) to close to $20K if you dont survive.

Here is the Ebola virus under a microscope. (Photo: Getty Images)

Thats why you never want to get infected by the Ebola virus. You can catch the virus from contacting the body fluids of an infected person, fruit bat, or non-human primate such as an ape or monkey. As the Centers for Disease Control and Prevention (CDC) explains, until now, the only thing that you could do to prevent an Ebola infection was to avoid the virus. That may be relatively easy in the U.S. where the Ebola virus so far has been exceedingly rare. However, that aint so easy in the middle of an outbreak such as the one that rocked West Africa from 2014 to 2016.

The Ebola vaccine works by exposing you to a form of the virus that cant cause an infection. This then prompts your immune system to in effect say, hmm, what is this? Oh, this doesnt look good. We should get prepared for when this virus returns. Think of Terry Benedict being shown the Oceans 11 crew and their plans before they even attempt the heist and how that would help the casino shore up defenses.

Health officials have been using the vaccine on an experimental basis to try to control Ebola outbreaks that have been going on in the Democratic Republic of the Congo (DRC). As described in this PBS Newshour segment, the war-torn DRC hasnt been the easiest place to test the vaccine:

Nevertheless, researchers managed to test the efficacy of the vaccine in the country. As the WHO reported in April, this vaccine had an estimated protective efficacy of 97.5% in field studies there. That would mean if a hundred people vaccinated were exposed to the virus, less than three would end up getting infected. Thats a remarkably high efficacy. After all, nothing in life is 100%. However, keep in mind that the efficacy of a vaccine also depends on how many people around you are vaccinated as weve seen with the measles vaccine as I have explained for Forbes previously.

Ebola and the Ebola vaccine didnt always get the attention that its getting today. In fact, as chronicled in the scientific journal CMAJ, the history of the Ebola vaccine reads sort of like an ugly duckling, Shes All That movie story line. It wasnt until the year 2001 that the Public Health Agency of Canadas National Microbiology Laboratory began in earnest attempts to develop an Ebola vaccine. Back then Ebola researchers struggled to secure funding because Ebola wasnt exactly a household name and working on the virus wasnt considered cool or sexy by the public and thus policy makers.

Despite these hurdles, the researchers at the Canadian laboratory persisted and by 2005 managed to develop a vaccine had perfect efficacy in protecting macaques, based on a study published in Nature Medicine. This was good news, for macaques. While these results were promising, much more work was necessary to proving that a vaccine could work in humans and be appropriately safe. Although the Canadian government had patented the vaccine, at the time, the future of the vaccine remained uncertain. It wasnt as if pharmaceutical companies were lining up to further develop the vaccine.

Everything changed in 2014 when the West Africa Ebola outbreak made international news. Suddenly, people in other continents began wondering and worrying about this deadly disease that could cause bleeding eyeballs. There were concerns about Ebola spreading to the U.S. and Europe. People who previously had never heard of Ebola were clamoring, do something, do something! Seemingly overnight, the previous wallflower Ebola vaccine had become the prom king or queen or at least someone invited to the prom. Merck then entered the picture to subsequently take the Canadian vaccine to the finish line and approval.

Having a major regulatory body like the European Commission approve the vaccine is a major step towards other regulatory bodies around the world following suit. The U.S. Food and Drug Administration (FDA) is currently reviewing Mercks application for approval. So stay tuned for news from the FDA by the first quarter of 2020 about possible approval in the United States.

The Ebola vaccine approval is a major public health success. As history has shown, the advent of a vaccine can dramatically dampen the spread of an infectious disease, in many cases taking it from a clear and present danger to something that people dont have to worry about on a regular basis. Just look at what happened to measles after the measles vaccine was introduced. Actually, just look at what happened to measles at least until 2000, before some people thought that it would be good idea to tell people to stop getting vaccinated.

Ervebo wont be a blockbuster money maker for Merck. Vaccines typically are far from the most profitable products for pharmaceutical companies, and the Ebola virus is far from common in higher income countries. Thus, the global health community will need to find ways to support and fund use of this vaccine. Alas, the Ebola vaccine will continue to face this and other obstacles after approval such as finding ways to get people vaccinated. Nevertheless, this approval news is still a big times big to the biggeth power step forward.

Read the original:
The Ebola Vaccine Is Now Officially Here With Approval In Europe - Forbes

Read More...

Interview with Wei Jian Goh of Craft Health on Personalized Medicine and Nutrition – 3DPrint.com

November 13th, 2019 6:52 am

Wei Jian Gohs startup Craft Health makes personalized medicine and nutrition possible. The startup is one Im very envious of as Ive had a lot of ideas in this area for years. Ideas are nothing however and the Singapore based Craft Health team is executing on a series of innovations that could make personalized nutrition and medicine more accessible and widespread. Craft Health is taking a very straightforward and logical idea to market: one pill does not fit all. If were both adults and we take a painkiller we may each take one, as prescribed. But I may be twice as heavy as you or my body could have a completely different in many different ways. Craft Health wants to enable the customization of pills and doses to the individual. Whats more the company wants to make their custom 3D printed pills commonplace. On top of that, the team have spotted a huge application which no one is working on in 3D printing: 3D printed nutrition and supplements. Craft Health is a very exciting startup to me that could really unlock many exciting outcomes for people in all sorts of scenarios. I love that it was started by pharmacists to enable them to better help patients. Im very bullish on the Singaporean startup so we interviewed Wei Jian Goh who is a co-founder and the CEO of the startup.

What is Craft Health?

Craft Health is a personalized nutrition and medicines platform, leveraging onto 3D printing technologies. Our vision is to simplify the process of pill taking for consumers or patients.

Where do you hope to be in five years?

We aim to be at the forefront of the intersection for 3D printing technologies and formulations, supplying the Craft Health solutions to both nutraceuticals and pharmaceutical industries.

CraftHealths CO-Founders, both Pharmacists, Wei Jiang Goh and Seng Han Lim.

What do you do?

Using 3D printing, we are able to print different shapes, layers or geometries to provide accurate dosing of active ingredients such as nutraceuticals or active pharmaceutical ingredients. We also compartmentalize individual active ingredients to reduce the risk of cross contamination or interactions. .

At the same time, we are also formulation scientists and have formulated different bases for various controlled release profiles.

These include immediate release (active ingredients are released within 10 minutes of consumption), sustained release (active ingredients are slowly released between 4-6 hours after consumption), amongst others.

We are also developing our very own 3D printer, using the paste extrusion technique where no heat nor UV curing is used. We are looking at how we can automate the 3D printing process in a scalable manner.

In short, we are able to personalize the nutrition or medicines to the consumer/patient.

How does it work?

Craft Health uses a proprietary blend of generally regarded as safe (GRAS) materials that are already found in the pills that are commercially available. We take the non-active ingredients of these pills and change their ratio in order to achieve different formulations of controlled release. For example, we have formulations for immediate release (release of active ingredients within 10 minutes after consumptions) and sustained release (release of active ingredients slowly over a period of 4 -6 hours). The active ingredient is blended into our proprietary formulations.

The active ingredients and our proprietary formulation for the selected release profile are blended and formed into a paste. The semi-solid paste is then extruded into the shape of a pill using a 3D printer. We are able to print multiple active ingredients, each with their selected release profiles, within the same pill in this way.

What would determine the individual supplements?

The individual supplements would be determined by the individual, on the basis of what they want (self-selection) and what they need (depending on their response for nutritional questionnaires and even nutrigenomics)

Would it depend on me, or me at one point, my blood work?

This would depend largely on the extent of personalization you require, from filling up a simple questionnaire to nutrigenomics.

Who are your customers?

Craft Health is targeting nutraceuticals and pharmaceutical companies to

1. License our technologies and 3D printed formulation solutions

2. Supply our 3D printed pills through the Craft Health Platform

What benefits would they have?

Nutraceuticals: Increase the product range to consumers, especially discerning consumers who are increasingly concerned about what supplements they take. Supplements can be in various combinations personalized to the individual, and also release profiles.

Pharmaceuticals: Rapid prototyping for reformulation exercise to extend existing patent life spans of therapeutics, or a low volume, high mix approach to clinical trials where small volumes batches and dosing can be titrated quickly, depending on the trial results.

Why did you start this company?

Craft Health is founded by two Singaporean pharmacists, who went on to pursue our PhDs in 3D printing and formulation work.

When we were practising as pharmacists, we saw many instances where patients go home with bags of medicines, typically from common conditions such as hypertension, diabetes and high cholesterol. This is further exacerbated by complicated dosing regimens such as before/after food requirements. We thought that there should be a better solution to this, something that can simplify the process of medicine taking and this, was the inspiration for Craft Health.

Who has funded you?

Craft Health has recently closed their seed fund raising round led by Mistletoe Singapore, and participated by National University of Singapore (NUS) Graduate Research Innovation Programme (GRIP) and one angel, NUS Adjunct Associate Professor Neo Kok Beng.

What does it feel like to be the first company in 3D printed nutrition?

We believe we are the first company in 3D printed nutrition in South East Asia. It is a humbling experience as we learn about the various nuances of consumer preferences in this region.

Do you think that 3D printed nutrition is for everyone? or just a select group of athletes?

We believe the early adopters will be those that require highly specialized nutrition. These include athletes where age, gender, sports type and even the stage of training matters. Eventually we see 3D printed nutrition for everyone, whether for maintaining good health or to optimize their performance.

When do you hope to launch a customer?

We are an early stage start up, having incorporated in May 2019. Currently we are in the research and development phase, where we are expanding our database of various formulations, developing our in-house 3D printer and also actively looking for collaborations and partnerships. Our target launch for our initial pilot for 3D printed supplements would be late 2020.

What magical sauce do you have that would stop me from copying you?

We believe we are one of the few companies that are developing the complete supply chain for 3D printed healthcare: From developing our very own 3D printers specializing in 3D printing nutraceuticals and pharmaceuticals, to developing our proprietary database of various formulations for controlled release of different active ingredients, whether supplements or pharmaceuticals. Therefore, we are able to offer a one stop solution for 3D printed healthcare.

Discuss this article and more on the 3DPrintBoard or comment below to tell us what you think.

See the article here:
Interview with Wei Jian Goh of Craft Health on Personalized Medicine and Nutrition - 3DPrint.com

Read More...

NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines – Pharmaceutical Business Review

November 13th, 2019 6:52 am

');},success: function(response) {$('.megamenuthird[data-menu=' + $data_megamenu + '-articles]').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + $data_megamenu + '-articles]').html("Error occured.please try again"); }});}}//Child Level Menu Hoverfunction get_childlevelmenu(currentid){//console.log('current id '+currentid);var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $('#'+currentid).closest('li').data('menu');var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';var submenu = $data_menu.split('-');var data_menu_class=submenu[0];//$('.megamenuthird').empty();$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('li.level_2').removeClass('activeli');$currentelement.closest('li').siblings().removeClass('activeli');$currentelement.closest('li').addClass('activeli');var current_megamenu_second = $('.megamenusecond[data-menu='+$data_menu+']').length;$('.megamenuopen .megamenusecond').removeClass('megamenusecond-show');//$currentelement.closest('li').find('.megamenuopen .megamenusecond').removeClass('megamenusecond-show');$('.megamenusecond[data-menu=' + $data_menu + ']').addClass('megamenusecond-show');//if(current_megamenu_seconda').html();/********* End level3 checking menu ********/// checking 4th level menu /*** 4th level Objec code here **///getting parent data-menuvar levelfour_data_menu = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_3.activeli').data('menu');// End getting parent data-menuvar subofSubChildLevel_cat_id = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('cat');var subofSubChildLevel_data_menu = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('menu');var subofSubChildLevel_taxnomy_type= $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('type');var subofSubChildLevel_title = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli>a').html();if(subofSubChildLevel_title!=''){var ajx_title=subofSubChildLevel_title;}else{var ajx_title=subChildLevel_title;}/*** End 4th level Objec code here **/if(subofSubChildLevel_cat_id!=''){var data_obj ={'title':ajx_title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}else{var data_obj ={'title':ajx_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}} if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({type: 'POST',url: 'https://www.pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts',data: data_obj, dataType: "html",beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent+ ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again");}});}//Subchild Level Menu Hover//Child Level Menu Hoverfunction get_subchildlevelmenu(currentid){var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $currentelement.closest('li').attr('data-menu'); var submenu = $data_menu.split('-'); var data_menu_class=submenu[0];var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('.megamenuthird').removeClass('megamenuthird-show');$('.megamenuthird[data-menu=' + $data_menu + ']').addClass('megamenuthird-show');$('li.level_3').removeClass('activeli');$currentelement.closest('li').addClass('activeli');var subChildLevel_title = $currentelement.html();//last child level$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').find('li.level_4').removeClass('activeli');var $data_menu = $('#'+currentid).closest('li').data('menu');$('.megamenuopen .megamenusecond-new').removeClass('megamenusecond-show');$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').addClass('megamenusecond-show');$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').find('li.level_4:first-child').addClass('activeli');//console.log('subchild-'+title);var subChildLevel_cat_id=$currentelement.closest('li').data("cat");var subChildLevel_taxnomy_type = $currentelement.closest('li').data("type");var ChildLevel_data_type= $(".mega-options > li.project_m.activeli").data("type");var ChildLevel_data_cat_id= $(".mega-options > li.project_m.activeli").data("cat_id");var parent_data_cat_id= $currentelement.closest('.themegamenu').data("main_cat_id");var parent_data_type= $currentelement.closest('.themegamenu').data("main_type");// checking 4th level menu /*** 4th level Objec code here **/// End getting parent data-menuif($('.megamenusecond.megamenusecond-new').length > 0){var subofSubChildLevel_cat_id = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('cat');var subofSubChildLevel_data_menu = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('menu');var subofSubChildLevel_taxnomy_type= $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('type');var subofSubChildLevel_title = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli>a').html();if(subofSubChildLevel_title!==''){var ajx_title=subofSubChildLevel_title;}else{var ajx_title=subChildLevel_title;}if(subofSubChildLevel_cat_id!=''){var data_obj= {'title':ajx_title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}else{var data_obj= {'title':ajx_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}}else{var data_obj= {'title':subChildLevel_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};} if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({ type: 'POST', url: 'https://www.pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts', dataType: "html", data: data_obj, beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again"); }});}//last child levelfunction get_lastchildlevelmenu(currentid){var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $currentelement.closest('li').attr('data-menu'); var submenu = $data_menu.split('-'); var data_menu_class=submenu[0];var $ajax_data_menu = $currentelement.closest('li').attr('data-ajax'); var ajax_submenu = $ajax_data_menu.split('-'); var ajax_data_menu_class=ajax_submenu[0]+'-'+ajax_submenu[1];var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('.megamenuthird').removeClass('megamenuthird-show');$('.megamenuthird[data-menu=' + $data_menu + ']').addClass('megamenuthird-show');$('li.level_4').removeClass('activeli');$currentelement.closest('li').addClass('activeli');var title = $currentelement.html();var subofSubChildLevel_cat_id=$currentelement.closest('li').data("cat");var subofSubChildLevel_taxnomy_type = $currentelement.closest('li').data("type");var subofSubChildLevel_title = $currentelement.closest('li').find('li.level_4.activeli>a').html();var subChildLevel_cat_id=$('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('cat');var subChildLevel_data_menu=$('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('menu');var subChildLevel_taxnomy_type = $('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('type');var ChildLevel_data_type= $(".mega-options > li.project_m.activeli").data("type");var ChildLevel_data_cat_id= $(".mega-options > li.project_m.activeli").data("cat_id");var parent_data_cat_id= $currentelement.closest('.themegamenu').data("main_cat_id");var parent_data_type= $currentelement.closest('.themegamenu').data("main_type");var data_obj= {'title':title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({ type: 'POST', url: 'https://www.pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts', dataType: "html", data:data_obj, beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again"); }});} $(document).ready(function(){//$('body').addClass('loaded');/********* End Third Level on over show/hide ****/$('.news-box-big').hover(function() {$(this).closest('.news').children('.big_title').toggleClass("bordertop");});$('.news-box-medium').hover(function() {$(this).closest('.medium_title').children('.tbt').toggleClass("bordertop");}); /********* Newsletter onclick events start here *******/ $(".header-cta a").click(function(e){ var $elem = $('.newsletter-box').position(); $('html,body').animate({ scrollTop: $(".newsletter-box").offset().top - 80}, 'fast'); }); /***** Newsletter onclick events End here *******/ /* Close guided tour */ $(".close-guided-tour").click(function(){$(".home_timeline").hide(); }); /* Close guided tour */ $(".close-guided-tour2").click(function(){ $(".timeline-tour2").hide(); }); /* $( ".fa-search" ).click(function() { $( 'body' ).toggleClass('search-open'); //$('.search-form').toggle(); }); $('.search-toggle').click(function () {$('.search-form').toggleClass('expanded');}); */ // Search toggle$('.navbar .search-toggle, .mobilesearch').click(function(e){e.preventDefault();$(this).parent().toggleClass('active').find('input[type="search"]').focus();});$('.search-submit').click(function(e){if( $(this).parent().find('.search-field').val() == '' ) {e.preventDefault();$(this).parent().parent().removeClass('active');}}); }); /* Reached newsletter */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.email-capture').offset().top - 50) { $('body').addClass("email-capture-reached"); } else{ $('body').removeClass("email-capture-reached"); } if($(this).scrollTop() >= $('.timeline').offset().top - 50) { $('body').addClass("timeline-tour-open"); } else{ $('body').removeClass("timeline-tour-open"); } }); }); /****** Article page Share n/w ********/ $('.social-toggle').on('click', function() { $(this).next().toggleClass('open-menu'); }); /*** End Article page Share n/w ********/ /* Close guided tour */ $(".close-guided-tour2").click(function(){ $("body").addClass("timeline-closed"); }); /* End Timeline guided tour Track the news */ /* Reached related headline */ $(function(){ $(document).ready(function(){ $('body').addClass("headline-reached"); }); }); /* Reached start */ /*$(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('#start').offset().top - 50) { $('body').addClass("start-reached"); } else{ $('body').removeClass("start-reached"); } }); });*/ /* Reached share-content */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.share-content').offset().top - 50) { $('body').addClass("share-content-reached"); } else{ $('body').removeClass("share-content-reached"); } }); }); /* share copy-link section */ function myFunction() { var copyText = document.getElementById("copylink"); copyText.select(); document.execCommand("Copy"); } /* Reached first sidebar mpu */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.mpu1').offset().top - 50) { $('body').addClass("reached-mpu1"); } else{ $('body').removeClass("reached-mpu1"); } }); }); /* Sticky sidebar banner */ /* $(function(){ $(document).scroll(function(){ if ($(window).width() > 1400) { if($(this).scrollTop() >= $('#sticky-mpu').offset().top - 250 ) { $('.sidebar').addClass("banner-fixed"); } else{ $('.sidebar').removeClass("banner-fixed"); } } }); });*/ // Select all links with hashes $('a[href*="#"]') // Remove links that don't actually link to anything .not('[href="#"]') .not('[href="#0"]') .click(function(event) { // On-page links if ( location.pathname.replace(/^//, '') == this.pathname.replace(/^//, '') && location.hostname == this.hostname ) { // Figure out element to scroll to var target = $(this.hash); target = target.length ? target : $('[name=' + this.hash.slice(1) + ']'); // Does a scroll target exist? if (target.length) { // Only prevent default if animation is actually gonna happen event.preventDefault(); $('html, body').animate({ scrollTop: target.offset().top }, 1000, function() { // Callback after animation // Must change focus! var $target = $(target); $target.focus(); if ($target.is(":focus")) { // Checking if the target was focused return false; } else { $target.attr('tabindex','-1'); // Adding tabindex for elements not focusable $target.focus(); // Set focus again }; }); } } }); /******** onclick share button in catgeory page ******/ $(".share-button").click(function(){ if($(this).parent('.open-share').length == 0){ $('.share').removeClass('open-share'); $(this).parent('.share').addClass("open-share"); }else{ $('.share').removeClass('open-share'); } }); /************* Mobile menu js *******/ function openNav() { document.getElementById("mobilemenu").style.width = "100%"; document.getElementById("mobilemenu").style.left = "0px"; } function closeNav() { document.getElementById("mobilemenu").style.width = "0"; } $( ".mobilemenuicon" ).click(function() { setTimeout(function(){ $( '.mobile-menu-cta' ).addClass("mobilectashow"); }, 500); }); $( ".closebtn" ).click(function() { $( '.mobile-menu-cta' ).removeClass("mobilectashow") }); /********** End mobile menu js *******/ /********* contractors Single page close Header**/ $(".close_section").click(function(){ $('.headersf').hide(1000); $('.headersf').addClass('section_closed'); $('.header-singleproduct').addClass('margin_top_added'); $('.small_header_sf').addClass('small_header_sf_display'); }); /******* End contractors Single page close Header**/ /*** My accout drop down menu */ $('.ctanav .dropdown-menu a').on('click', function() { window.location.href = $(this).attr('href'); }); /*** cookie-popup **/ $("#cookiepopup-continue").click(function(){ $.cookie("cookie_compelo", 'https://www.pharmaceutical-business-review.com'); $('.home_timeline').hide(); }); $(window).on("load",function(){ var data = $.cookie("cookie_compelo"); if(data){ $('.home_timeline').hide(); }else{ $('.home_timeline').show(); } }); $(".home_timeline .close").click(function(){ $.cookie("cookie_compelo", 'https://www.pharmaceutical-business-review.com'); $('.home_timeline').hide(); }); $(window).on("load",function(){ var data = $.cookie("cookie_compelo"); if(data){ $('.home_timeline').hide(); }else{ $('.home_timeline').show(); } }); /*** End cookie popup **/ /**** New add js code ***/ if ($(window).width() > 960) { // Initialization $(function(){ $('[data-scroll-speed]').moveIt(); }); } /* Sticky sidebar banner EVENT PAGE */ $(function(){ $(document).scroll(function(){ var scroll = $(window).scrollTop(); if (scroll >= 655) { $('.sticky-mpu-event').addClass("banner-fixed"); } else{ $('.sticky-mpu-event').removeClass("banner-fixed"); } }); }); //advertising page jQuery.fn.moveIt = function(){ var $window = jQuery(window); var instances = []; jQuery(this).each(function(){ instances.push(new moveItItem($(this))); }); window.addEventListener('scroll', function(){ var scrollTop = $window.scrollTop(); instances.forEach(function(inst){ inst.update(scrollTop); }); }, {passive: true}); } var moveItItem = function(el){ this.el = jQuery(el); this.speed = parseInt(this.el.attr('data-scroll-speed')); }; moveItItem.prototype.update = function(scrollTop){ this.el.css('transform', 'translateY(' + -(scrollTop / this.speed) + 'px)');};// InitializationjQuery(function(){jQuery('[data-scroll-speed]').moveIt();}); /**** end new add js code **/

Read more:
NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines - Pharmaceutical Business Review

Read More...

Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019 – GlobeNewswire

November 13th, 2019 6:52 am

PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Companys financial results and provide a general business update.

All listeners should confirm they are dialing in for the Interpace conference call with the operator who will promptly place them into the call. A webcast replay will be available on the companys website (www.interpacediagnostics.com) approximately two hours following completion of the call and will be archived on the companys website for 90 days.

About Interpace, Inc.

Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpaces Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDXthat differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpaces Biopharma Business is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpaces website at http://www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

Read this article:
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019 - GlobeNewswire

Read More...

Nonsmoking mom thought she had asthma, it was lung cancer – TODAY

November 13th, 2019 6:52 am

In the fall of 2017, Brandi Bryant had a nagging cough. It seemed mild enough that it would go away on its own, but she began to worry when she also started experiencing shortness of breath.

It was a tiny bit annoying, Bryant, 41, of Atlanta, told TODAY. Nothing that really bothered me or a cough so bad like bronchitis.

Bryant suspected she had developed asthma. But, the doctors thought it might be pulmonary fibrosis, a lung disease that causes scarring, which makes it difficult to breath. She tried to research it, but her symptoms didnt seem to fit.

Dr. Google said it was cancer," she said. "But, it didnt make any sense for me."

I was exercising OK, I was able to do everything, like running after my children, Bryant added. Even the pulmonologist said in the first appointment, This isnt cancer ... Its got to be something else.

Her doctors kept searching. They ordered a CT scan and followed up with a bronchoscopy to look directly into her airways. By this point, Bryant wondered if she had a disease like tuberculosis or even worse.

When she returned to look at the results, she sensed the doctor seemed sober. That's when she was told she had stage 3B lung cancer.

Bryant was stunned by the news, in part because she never smoked. She calls herself the judgiest of judges when it comes to smokers.

Trending stories,celebrity news and all the best of TODAY.

I run away when I see people smoking ... I didnt understand why you cant stop smoking, she said. "To have a cancer that we have been told that its only cause is smoking, I was blown away. I was completely devastated.

She started chemotherapy and radiation, but after her fourth round of chemotherapy she developed fluid around her heart and lungs. When doctors drained the fluid, they found it had cancer in it, too, and Bryant now had stage 4 cancer. Genomic testing revealed that it was anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer. People under 55 who never smoked are most likely to have this form of cancer, according to the Lung Cancer Foundation of America.

Going from stage 3, hoping for a cure, to stage 4 and you are incurable until you die ... It was overwhelming, she said. It was really, really tough.

Looking back, Bryant had thought her symptoms seemed mild, but her ex-husband mentioned months before her diagnosis that she coughed throughout the night. It hadnt been disrupting her sleep or how she felt, so she thought it was something small and never sought help for it.

I was so busy and taking care of the family. It didnt bother me, Bryant explained. It was not a priority. It is what we as women do.

Breaking the news about the cancer to her four children Amelie, 17, Karsyn, 11, Gabrielle, 9, and Ken, 5 was tough.

The hardest things, of course, was telling them, she said. The first thing my second daughter asked me was, Are you going to die? The hardest thing was me saying that I cant promise her. I dont know.

For a year and a half, Bryant has been on a therapy that targets the ALK mutation and has shrunk her tumors, meaning that, for now, there's no detectable cancer in her body.

The focus of lung cancer treatments is to stop it from spreading, according to Dr. D. Ross Camidge, director of thoracic oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center, who did not treat Bryant.

"If the cancer has spread to other organs ... control, not cure, is the goal, he told TODAY via email. For some subtypes of lung cancer, like ALK, that control can be measured in years.

Expanded treatment options like genomic testing and targeted therapy are giving lung cancer patients better chances, Camidge added.

"Lung cancer is not one disease anymore, he said. Dividing it into different [types], based on the cancers genes, has been the key to the success of personalized medicine. Long-term control is much easier when you are individualizing treatment approaches to each patient.

For Bryant, she knows that the effects of her therapy are likely to last about three years and that treatment options are limited beyond this step. She hopes that sharing her story will help increase resources to investigate all lung cancers.

I am hoping we can do some more research and have more than one option available, she said.

Throughout her treatment, Bryant has continued to work and enjoy time with her family. She adopted a dog and took her children to Paris.

Im definitely more of a live-in-the-moment person, I realize that life is fragile for all of us," she said. "We just dont realize until it touches you in some way, where there is some kind of tragedy or you have a diagnosis that is life limiting."

Even though her future remains unclear, she stays positive and is making memories: The biggest thing I have done is I am present with my children."

See the original post:
Nonsmoking mom thought she had asthma, it was lung cancer - TODAY

Read More...

Simulation-based Method To Target Epilepsy Goes to Clinical Trials – Technology Networks

November 13th, 2019 6:52 am

A novel method to improve outcomes of surgery to treat epilepsy has now received approval for clinical testing in 13 French hospitals. The approach could provide a better therapeutic perspective against the drug-resistant form of the disease, which constitutes one-third of all cases, and is a development by Human Brain Project scientist Viktor Jirsa and an interdisciplinary team of collaborators.

To help clinicians plan surgery strategies, the scientists created personalized brain models of patients and simulate the spread of abnormal activity during epileptic seizures. The method represents the first example of a personalized brain modeling approach entering the clinic and will now be assessed over four years in a cohort of 356 patients under strict requirements.

How do we currently treat epilepsy?

Epilepsy is a wide-spread neurological disorder that affects around 50 million people worldwide. In many cases, the seizures that mark the disease can be controlled by drugs, but close to a third of all patients are drug-resistant. For them, the only remaining option is surgical removal of the epileptogenic zone, the area from which the seizure activity first emerges and then spreads. During surgery preparation it is critical to localize this area as precisely as possible in the brain, but very challenging with current methods. As a result, surgery outcomes are difficult to predict, with success rates of only around 60%.

This low success rate has largely stayed the same for the last 30 years. We hope our approach can finally improve the odds for patients, says Jirsa. In the Human Brain Project, Jirsa is the Deputy Leader of the research area of Theoretical Neuroscience.

The Human Brain Project and The Virtual Brain

Over the last five years and in large part within the framework of the Human Brain Project, Jirsa and his team worked on an approach that could bring a change. The team has adapted the open network simulator The Virtual Brain towards applications in epilepsy. This work has laid foundations for the project EPINOV, short for Improving EPilepsy surgery management and progNOsis using Virtual brain technology, a consortium coordinated by Fabrice Bartolomei (Hpital de la Timone) that brings together theorists like Jirsa, clinical neuroscientists, in particular from Marseille and Lyon, and the industry partner Dassault Systmes.

After two pilot studies showed promising results for the approach, the EPINOV-consortium has received approval from the French regulatory authority to put their approach to the test in a full-scale multi-centric trial with almost 400 prospective patients.

It represents the worlds first clinical trial ongoing using full brain network modeling, says Jirsa. When the authorization came in, it was like a huge pressure was relieved from me after all this hard work. Then followed last preparations to assure that all steps in the workflow of virtualization and evaluation of the patient brains are in order during the four-year period of the trial.

Bartolomei explains "This type of epilepsy affects millions of patients worldwide. The personalized modeling of epilepsy networks in drug-resistant patients is an innovative and scientifically validated approach, which proposes to enrich the interpretation of neurophysiological and neuroimaging tests, and thus to improve the surgical prognosis of epilepsy in an individualized way".

Jirsa and his close collaborators, Randy McIntosh at Baycrest Center Toronto and Petra Ritter at Charit Berlin, started building The Virtual Brain as an open-source brain network simulation engine from 2010 on, using neuronal population models and structural information from neuroimaging.

In the Human Brain Project environment, the conditions were perfect to go the decisive steps further towards applying it in a clinical context. The science underlying this trial is almost entirely a result of our work in the HBP, Jirsa says.

Simulating epilepsy

First, a personalized brain model is created from data on the individually measured anatomy, structural connectivity and brain dynamics for each patient. Through a series of steps, it is turned into a dynamic model, on which the seizure propagation can be simulated. High-Performance Computing enables the personalization of the brain network models through the application of machine learning.

The resulting brain avatar is customized to the individual patient and allows testing and estimating during surgery preparation. In a small cohort of retrospective surgery patients we were able to demonstrate that the predictions of the patients brain model correlate well with positive surgery outcome, Jirsa explains, and other labs have confirmed our results independently.

In half of the cases, the surgeons will have information from the epilepsy-model in their staff meetings, where therapeutic interventions are planned. It's a blind random design, half of these patients will be operated taking our model predictions into account, the other half will not. After four years, the statistics will show us hopefully to what degree the model predictions changed the surgery practice, results, and outcome, Jirsa says.

Within the EPINOV consortium, the industrial partner Dassault Systmes will develop a virtual brain-based simulation software prototype that could subsequently be provided to clinics worldwide. Headquartered in France, Dassault Systmes is a multinational software company focused on 11 industries including life sciences and the development of patient-centric modeling and simulation experiences.

There is a very big responsibility, Jirsa emphasizes and at the same time its very exciting that we have this chance to improve clinical practice and ultimately patients lives. And if the approach succeeds, it would also be the first modelling-based example of personalized medicine that makes the jump from research to clinical practice so the outcome will certainly be a signal to the field.

Katrin Amunts, Scientific Research Director of the Human Brain Project, highlights the significance of the move into the clinic: This breakthrough by Viktor Jirsa and his colleagues is a fantastic example of a new type of technology-enabled computational neuro-medicine. It is one of our central aims to catalyze developments like this that make concrete contributions in the fight against brain diseases to benefit patients.

Philippe Ryvlin, who leads the Medical Informatics Platform in HBP and the epilepsy surgery section of the European Reference Network EpiCARE emphasizes that this clinical trial, which will be the largest randomized study ever performed in epilepsy surgery, demonstrates that simulation of the human brain, as developed in HBP, has now reached a stage where it can be readily applied to address unmet medical needs.

Virtual Brain Researchers are also continuing their activities on clinical modeling for stroke and Alzheimers in collaboration with experts that the HBP brings together. For Jirsa seeing his work as a theoretical scientist gain this potential impact has been the result of a unique convergence: That we have come to this point was made possible by clinical expertise and our activities on The Virtual Brain and the Human Brain Project all coming together right place, right time, right people."

Reference

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Originally posted here:
Simulation-based Method To Target Epilepsy Goes to Clinical Trials - Technology Networks

Read More...

Purdue researchers develop map to make getting cancer drugs to the brain easier – Purdue Exponent

November 13th, 2019 6:52 am

The biggest difficulty when treating cancer in the brain is the blood-brain barrier, a group of blood vessels that filter what enters and leaves the brain.

When cancer cells enter the brain, the blood-brain barrier becomes a blood-tumor barrier, which creates another obstacle for effectively getting cancer drugs to the brain.

A team at Purdue has developed an extensive identification of the blood-brain and blood-tumor barriers that interfere in brain metastases of lung cancer, which will provide a guide for developing treatments. The research was published in Oncotarget, a bio-medical journal that primarily publishes research on oncology.

Tiffany Lyle, an assistant professor in the College of Veterinary Science, led the team of scientists. Her work is centered on the pathology of the blood-brain barrier.

Brain metastases occur most frequently in patients diagnosed with breast and lung cancer and melanoma, Lyle said in a Purdue press release. She went on to explain that the metastases have a high survival rate, mainly because the blood-barrier makes it extremely difficult to get medication into the brain tissue.

Brain metastases, also known as secondary brain tumors, develop when cancer cells spread from their point of origin and into the brain. This is occurs in between 10% and 30% of adult cancer cases, according to the Mayo Clinic.

The researchers analyzed blood-brain and blood-tumor barriers in animal models using non-small-cell cancer cells, which make up the majority of lung cancers, and immunofluorescent imaging. They confirmed their results by studying blood-tumor barriers of brain metastases in brain tissue from cadavers.

We wanted to see what changes in the blood-brain barrier were occurring rapidly and which ones were sustained over time, Lyle said. Identifying those changes and pinpointing when they occur during the transition will be critical to developing treatment plant and being able to identify where, and when, cancer cells need to be targeted.

Lyle added that until the teams discovery, the blood-tumor barrier had not been properly identified in lung cancer.

During their analysis, the team observed that one of the changes in the blood-brain barrier to the blood-tumor barrier occurred in the astrocytes, one of the largest cells in the brain that serve a variety of functions. Lyle commented that this discovery alone will serve a key role in the development of future cancer treatment in the brain, as it shows the scientists where and when the brain prevents drugs from entering.

A goal of our research is to meaningfully contribute to the evolving field of personalized medicine and provide patients who have received a devastating diagnosis a sense of home for treatment possibilities, Lyle said.

More here:
Purdue researchers develop map to make getting cancer drugs to the brain easier - Purdue Exponent

Read More...

Page 836«..1020..835836837838..850860..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick